Literature DB >> 22323984

Psychological Co-morbidity in Functional Gastrointestinal Disorders: Epidemiology, Mechanisms and Management.

Justin Cy Wu1.   

Abstract

Functional gastrointestinal disorder (FGID) is one of the commonest digestive diseases worldwide and leads to significant morbidity and burden on healthcare resource. The putative bio-psycho-social pathophysiological model for FGID underscores the importance of psychological distress in the pathogenesis of FGID. Concomitant psychological disorders, notably anxiety and depressive disorders, are strongly associated with FGID and these psychological co-morbidities correlate with severity of FGID symptoms. Early life adversity such as sexual and physical abuse is more commonly reported in patients with FGID. There is mounting evidence showing that psychological disorders are commonly associated with abnormal central processing of visceral noxious stimuli. The possible causal link between psychological disorders and FGID involves functional abnormalities in various components of the brain-gut axis, which include hypothalamic-pituitary-adrenal system, sympathetic and parasympathetic nervous system, serotonergic and endocannabinoid systems. Moreover, recent studies have also shown that psychological distress may alter the systemic and gut immunity, which is increasingly recognized as a pathophysiologic feature of FGID. Psychotropic agent, in particular antidepressant, and psychological intervention such as cognitive behavioral therapy and meditation have been reported to be effective for alleviation of gastrointestinal symptoms and quality of life in FGID patients. Further studies are needed to evaluate the impact of early detection and management of co-morbid psychological disorders on the long-term clinical outcome and disease course of FGID.

Entities:  

Keywords:  Depression; Functional dyspepsia; Generalized anxiety disorder; Irritable bowel syndrome; Psychological disorder

Year:  2012        PMID: 22323984      PMCID: PMC3271249          DOI: 10.5056/jnm.2012.18.1.13

Source DB:  PubMed          Journal:  J Neurogastroenterol Motil        ISSN: 2093-0879            Impact factor:   4.924


  59 in total

1.  Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  Hyuk Lee; Jeong Hwan Kim; Byung-Hoon Min; Jun Haeng Lee; Hee Jung Son; Jae J Kim; Jong Chul Rhee; Young Ju Suh; Seonwoo Kim; Poong-Lyul Rhee
Journal:  Am J Gastroenterol       Date:  2010-03-23       Impact factor: 10.864

Review 2.  How do SSRIs help patients with irritable bowel syndrome?

Authors:  F Creed
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

3.  Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome.

Authors:  Uri Ladabaum; Annie Sharabidze; Theodore R Levin; Wei K Zhao; Elaine Chung; Peter Bacchetti; Chengshi Jin; Barbara Grimes; Craig J Pepin
Journal:  Clin Gastroenterol Hepatol       Date:  2009-09-16       Impact factor: 11.382

4.  Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial.

Authors:  Susan A Gaylord; Olafur S Palsson; Eric L Garland; Keturah R Faurot; Rebecca S Coble; J Douglas Mann; William Frey; Karyn Leniek; William E Whitehead
Journal:  Am J Gastroenterol       Date:  2011-06-21       Impact factor: 10.864

5.  Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress.

Authors:  I Posserud; P Agerforz; R Ekman; E S Björnsson; H Abrahamsson; M Simrén
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

6.  Validation of Self-administrated Questionnaire for Psychiatric Disorders in Patients with Functional Dyspepsia.

Authors:  Ada W Y Tse; Larry H Lai; C C Lee; Kelvin K F Tsoi; Vincent W S Wong; Yawen Chan; Joseph J Y Sung; Francis K L Chan; Justin C Y Wu
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

7.  Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia.

Authors:  J G Hashash; H Abdul-Baki; C Azar; I I Elhajj; L El Zahabi; H F Chaar; A I Sharara
Journal:  Aliment Pharmacol Ther       Date:  2008-03-10       Impact factor: 8.171

8.  Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study.

Authors:  Pertti Aro; Nicholas J Talley; Jukka Ronkainen; Tom Storskrubb; Michael Vieth; Sven-Erik Johansson; Elisabeth Bolling-Sternevald; Lars Agréus
Journal:  Gastroenterology       Date:  2009-03-26       Impact factor: 22.682

9.  No difference in symptoms of irritable bowel syndrome between healthy subjects and patients with recurrent depression in remission.

Authors:  P Karling; A Danielsson; R Adolfsson; K-F Norrback
Journal:  Neurogastroenterol Motil       Date:  2007-07-18       Impact factor: 3.598

10.  Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial.

Authors:  Gary Tabas; Mary Beaves; Jiping Wang; Paul Friday; Houssam Mardini; George Arnold
Journal:  Am J Gastroenterol       Date:  2004-05       Impact factor: 10.864

View more
  39 in total

Review 1.  The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both?

Authors:  Giada De Palma; Stephen M Collins; Premysl Bercik; Elena F Verdu
Journal:  J Physiol       Date:  2014-04-22       Impact factor: 5.182

2.  The Microbiome, Gut-Brain-Axis, and Implications for Brain Health.

Authors:  Sarah Prinsloo; Randall R Lyle
Journal:  NeuroRegulation       Date:  2015

3.  Interactions of early adversity with stress-related gene polymorphisms impact regional brain structure in females.

Authors:  Arpana Gupta; Jennifer Labus; Lisa A Kilpatrick; Mariam Bonyadi; Cody Ashe-McNalley; Nuwanthi Heendeniya; Sylvie Bradesi; Lin Chang; Emeran A Mayer
Journal:  Brain Struct Funct       Date:  2015-01-30       Impact factor: 3.270

Review 4.  The interplay between the intestinal microbiota and the brain.

Authors:  Stephen M Collins; Michael Surette; Premysl Bercik
Journal:  Nat Rev Microbiol       Date:  2012-09-24       Impact factor: 60.633

Review 5.  The microbiota-gut-brain axis in functional gastrointestinal disorders.

Authors:  Giada De Palma; Stephen M Collins; Premysl Bercik
Journal:  Gut Microbes       Date:  2014-06-12

6.  Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency.

Authors:  Maria Ines Pinto-Sanchez; Alexander C Ford; Christian A Avila; Elena F Verdu; Stephen M Collins; David Morgan; Paul Moayyedi; Premysl Bercik
Journal:  Am J Gastroenterol       Date:  2015-05-12       Impact factor: 10.864

7.  Effect of clinician-patient communication on compliance with flupentixol-melitracen in functional dyspepsia patients.

Authors:  Xiu-Juan Yan; Wen-Ting Li; Xin Chen; Er-Man Wang; Qing Liu; Hong-Yi Qiu; Zhi-Jun Cao; Sheng-Liang Chen
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

8.  Increase in plasma acyl ghrelin levels is associated with abatement of dyspepsia following Helicobacter pylori eradication.

Authors:  Yoon Jin Choi; Nayoung Kim; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Ji Hyun Park; Ryoung Hee Nam; Dong Ho Lee; Hyun Chae Jung
Journal:  J Gastroenterol       Date:  2015-09-28       Impact factor: 7.527

Review 9.  Postural tachycardia syndrome: a heterogeneous and multifactorial disorder.

Authors:  Eduardo E Benarroch
Journal:  Mayo Clin Proc       Date:  2012-11-01       Impact factor: 7.616

Review 10.  Gut Microbiome: What We Do and Don't Know.

Authors:  Gail A Cresci; Emmy Bawden
Journal:  Nutr Clin Pract       Date:  2015-10-08       Impact factor: 3.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.